In a UK marketplace filled with innovation and multiple indications for molecules – sometimes across multiple clinical areas - companies have to work ever harder to find a place in therapy for their product.
Where your medicine sits in terms of “line of therapy” – first, second, third, fourth or beyond – will have a huge impact on sales and usage.
What’s been difficult to establish – until now – is how many medicines are being prescribed at these lines, and how many patients stand to benefit from your medicine should their prescriber switch them.
HSJ’s SSD can now tell you how many patients are currently on successive “lines” of therapy – and give you this crucial market access lens.
In this article, you can find out more.